Zinda Michael 4
4 · Repare Therapeutics Inc. · Filed Dec 6, 2021
Insider Transaction Report
Form 4
Zinda Michael
EVP, CHIEF SCIENTIFIC OFFICER
Transactions
- Exercise/Conversion
Common Shares
2021-11-23$1.64/sh+4,122$6,748→ 4,655 total - Exercise/Conversion
Common Shares
2021-11-23$2.06/sh+19,590$40,395→ 36,101 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-23−4,122→ 0 totalExercise: $1.64Exp: 2027-06-14→ Common Shares (4,122 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-23−19,590→ 35,260 totalExercise: $2.06Exp: 2029-03-29→ Common Shares (19,590 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-23−10,473→ 137,993 totalExercise: $2.42Exp: 2029-12-16→ Common Shares (10,473 underlying) - Exercise/Conversion
Common Shares
2021-11-23$1.64/sh+11,856$19,408→ 16,511 total - Exercise/Conversion
Common Shares
2021-11-23$2.42/sh+10,473$25,397→ 46,574 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-11-23−11,856→ 0 totalExercise: $1.64Exp: 2027-12-04→ Common Shares (11,856 underlying)
Footnotes (3)
- [F1]Fully vested and exercisable.
- [F2]Twenty-five percent (25%) of the shares subject to the option vested on March 29, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option vested or shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
- [F3]Twenty-five percent (25%) of the shares subject to the option vested on December 16, 2020, and one thirty-ninth (1/39th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.